Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions.
Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is eligible to receive up to $2.1 billion in upfront and milestone payments, along with tiered royalties tied to future net sales, according to a Feb. 25 news release.
The collaboration aims to enable oral delivery of peptide and protein therapeutics that are typically limited to injections because of low gastrointestinal absorption. Vivtex’s platform combines high-throughput gastrointestinal screening, drug delivery technologies and AI-driven analytics designed to improve oral bioavailability and performance.
Novo Nordisk will lead global development, regulatory activities, manufacturing and commercialization of any resulting products.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
